116 related articles for article (PubMed ID: 21790326)
1. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe.
Holló G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babić N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V; Januleviciene I; Kóthy P; Camara C; Russo A; Krzyzanowska-Berkowska P; Cieślińska I; Stewart JA; Kristoffersen MS; Nelson LA; Stewart WC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):493-8. PubMed ID: 21790326
[TBL] [Abstract][Full Text] [Related]
2. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
4. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
J Glaucoma; 2010 Mar; 19(3):199-206. PubMed ID: 19661825
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
6. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
7. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
10. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
11. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients.
Martinez A; Sanchez M
Eye (Lond); 2009 Apr; 23(4):810-8. PubMed ID: 18535605
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
14. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects.
Halpern MT; Covert DW; Robin AL
Trans Am Ophthalmol Soc; 2002; 100():109-17; discussion 117-8. PubMed ID: 12545683
[TBL] [Abstract][Full Text] [Related]
15. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
Chiseliţă D; Antohi I; Medvichi R; Danielescu C
Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
18. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
Orme M; Collins S; Loftus J
J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
[TBL] [Abstract][Full Text] [Related]
19. Observational study of patients switched to the fixed travoprost 0.004%/timolol 0.5% combination in Croatia.
Mandic Z; Novak-Lauš K; Bojic L; Popovic-Suic S; Maricic-Došen V; Pelcic G; Dobutovic D; Biuk D; Kovacic Z; Pavan J
Methods Find Exp Clin Pharmacol; 2010 Oct; 32(8):593-8. PubMed ID: 21132129
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range.
Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB
Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
